Orchid Pharma Board Approves Q4 FY26 Financials, Appoints Internal Auditor
Orchid Pharma reported audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Standalone net sales for the year were ₹81,132.73 lakhs. The company appointed an Internal Auditor for FY27. Key developments include the completion of Allecra Therapeutics acquisition and an update on the Dhanuka Laboratories amalgamation.
The financial results, appointment of an auditor, and significant acquisitions like Allecra Therapeutics are material events. The qualified audit opinion on consolidated results adds a layer of complexity.
The announcement reports financial results and corporate actions. While the results themselves are neutral, the qualified opinion on consolidated results introduces a note of caution.
Orchid Pharma Limited announced the outcome of its Board Meeting held on May 25, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. These results include the statement of assets & liabilities and cash flow statement, accompanied by auditors' reports from M/s. Singhi & Co. The Board also approved the appointment of the Internal Auditor for the Financial Year 2026-27.
The financial results for the quarter ended March 31, 2026, show standalone net sales of ₹23,760.73 lakhs and consolidated net sales of ₹23,760.73 lakhs. For the full financial year ended March 31, 2026, standalone net sales were ₹81,132.73 lakhs and consolidated net sales were ₹81,132.73 lakhs. The company reported a standalone profit before tax of ₹4,520.79 lakhs for the year, and a consolidated profit before tax of ₹2,101.67 lakhs for the year.
Key notes from the financial statements include the reversal of an excess provision of ₹53.92 lakhs related to labor codes in the March 2026 quarter, impacting exceptional items. The company also provided an update on its amalgamation petition with Dhanuka Laboratories Limited, stating that the National Company Law Tribunal (NCLT) has reserved its order. Furthermore, Orchid Pharma successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH and Allecra Therapeutics SAS, consolidating global ownership of Enmetazobactam (EXBLIFEP). The company also acquired 100% share capital of Weilchensee 1272. V V GmbH, now renamed Orchid Pharma Europe GmbH.
The statutory auditors issued an unmodified opinion on the standalone financial results and a qualified opinion on the consolidated financial results, citing that the financial statements of certain subsidiaries were unaudited and provided by management.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.